Samsung Medical Center

ImmuneOncia Announces Biomarker Results from Phase 1 Clinical Trial of CD47 Antibody at ASCO

Retrieved on: 
Lundi, juin 3, 2024
Biotechnology, Pharmaceutical, Oncology, Health, Artificial Intelligence, Health Technology, Technology, Clinical Trials, Therapy, Breast cancer, ASCO, DCR, CBR, Hepatocellular carcinoma, Multimedia, Toxicity, Prognosis, Patient, Annual general meeting, ESMO, Cancer, Neutropenia, Society, Thrombocytopenia, Clinical trial, Anemia, Samsung Medical Center, CD47, Infrared spectroscopy correlation table, Pharmaceutical industry

ImmuneOncia (CEO Heung Tae Kim) announced the results of its solid tumour Phase 1a clinical trial of IMC-002, an anti-CD47 mAb, presented at the American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, USA on June 1, 2024 (local time).

Key Points: 
  • ImmuneOncia (CEO Heung Tae Kim) announced the results of its solid tumour Phase 1a clinical trial of IMC-002, an anti-CD47 mAb, presented at the American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, USA on June 1, 2024 (local time).
  • These results include updates on the Phase 1a clinical trial outcomes, along with biomarker findings achieved through collaboration with Lunit (CEO; Brandon Suh), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics.
  • View the full release here: https://www.businesswire.com/news/home/20240603017832/en/
    ImmuneOncia Announces Biomarker Results from Phase 1 Clinical Trial of CD47 Antibody at ASCO (Graphic: ImmuneOncia Therapeutics, Inc.)
    The study, a dose escalation part of Phase 1, enrolled a total of 12 patients across four dose cohorts starting from May 2022.
  • He further stated, "With the Phase 1b trial for IMC-002 initiated last November, we anticipate additional efficacy confirmation for IMC-002 in specific solid tumours with high unmet needs."

Inocras Presents Poster for Breast Cancer at 2024 ASCO Annual Meeting, Showing Transformative Impact of WGS-based HRD Testing

Retrieved on: 
Samedi, juin 1, 2024
Oncology, Data Management, Health, Technology, Health Technology, Genetics, Biotechnology, Patient, ADP, Breast MRI, Inc., BRCA2, MRI, Breast cancer, Whole genome sequencing, Samsung Medical Center, MRD, WGS, Research, Breast, Cancer, Medicine, Biomarker, ASCO, Gene, BRCA1, Hospital, Woman, Society, DCE, Multimedia, HRD, Annual general meeting, Medical imaging

View the full release here: https://www.businesswire.com/news/home/20240531817764/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240531817764/en/
    In collaboration with Samsung Medical Center and St. Mary’s Hospital, Inocras' research study recruited 145 women with invasive breast cancer.
  • Researchers utilized dynamic contrast-enhanced (DCE) breast MRI to explore the relationship between HRD and specific radiomic features.
  • HRD, a crucial target in breast cancer treatment, involves key genes known as BRCA1 and BRCA2, whose pathogenic mutations are crucial features for selecting poly (ADP-ribose) polymerase inhibitors (PARPi) treatment.
  • “This research underscores the transformative impact of WGS-based HRD testing, allowing for a more comprehensive view of HRD and the development of better evaluation and screening tools,” said Inocras co-founder Jeong Seok Lee.

The Shared & Unlicensed Spectrum LTE/5G Network Ecosystem Report 2023-2030: Global Opportunities, Challenges, Strategies & Forecasts - ResearchAndMarkets.com

Retrieved on: 
Lundi, janvier 15, 2024
5G, IOT (Internet of Things), Mobile, Wireless, Technology, Telecommunications, National Football League, SGCC, Social media, Osaka Gas, Sveriges Television, Microsoft Excel, Mercedes-Benz, MVNO, Health, ArcelorMittal, NFL, SDG, FWA, Volkswagen, SMC, SDG&E, Mining, International airport, BMW, Sport, GAA, EDF, BBC, Transport, LTE, Public sector, Samsung Medical Center, White space, Education, Mitsubishi Group, Agriculture, Airbus, CBRS, HKIA, High-pass filter, Korea Electric Power Corporation, Lufthansa, Mobile virtual network operator, Hertz, Radio access network, Ferrovial, Dow, RAN, Groupe ADP, Meta, 3GPP, Ecosystem, Ricoh, Shared, SVT, Mobile phone

The "The Shared & Unlicensed Spectrum LTE/5G Network Ecosystem 2023-2030: Opportunities, Challenges, Strategies & Forecasts" report from SNS Telecom & IT has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "The Shared & Unlicensed Spectrum LTE/5G Network Ecosystem 2023-2030: Opportunities, Challenges, Strategies & Forecasts" report from SNS Telecom & IT has been added to ResearchAndMarkets.com's offering.
  • The report estimates that global investments in 5G NR and LTE-based RAN (Radio Access Network) infrastructure operating in shared and unlicensed spectrum will account for more than $1.4 Billion by the end of 2023.
  • The report also provides global and regional forecasts for shared and unlicensed spectrum LTE/5G RAN infrastructure from 2023 to 2030.
  • The report comes with an associated Excel datasheet suite covering quantitative data from all numeric forecasts presented in the report.

New Study Finds Significant Correlation Between Masimo ORi™ and Arterial Partial Pressure of Oxygen During One-Lung Ventilation

Retrieved on: 
Lundi, décembre 11, 2023
Biotechnology, Surgery, Health, Pharmaceutical, Health Technology, Odds ratio, Samsung Medical Center, De novo, Blood, OLV, Sungkyunkwan University, Hypoxemia, Risk, MASI, Patient, Multimedia, Journal, FDA, Hyperoxia, Oxygen, Blood gas tension, Perioperative, Ori, Oxygen saturation (medicine), Receiver operating characteristic, Medical device, Medical imaging, Anesthesia, ROC

ORi is trended continuously with SpO2 as a unit-less index between 0.00 and 1.00 to extend the visibility of the patient oxygenation beyond SpO2 under supplemental oxygen.

Key Points: 
  • ORi is trended continuously with SpO2 as a unit-less index between 0.00 and 1.00 to extend the visibility of the patient oxygenation beyond SpO2 under supplemental oxygen.
  • During anesthesia, ORi was monitored using Masimo RD rainbow SET® Pulse CO-Oximetry sensors, and blood gas analysis was performed 15 minutes after OLV was initiated.
  • Of the 11 potential predictors for PaO2
  • The researchers concluded, “ORi values during one-lung ventilation were significantly correlated with PaO2 measured simultaneously.

Guardant Health launches Shield blood-based screening test for colorectal cancer in South Korea

Retrieved on: 
Lundi, novembre 13, 2023
Shield, DNA, Colorectal cancer, Neoplasm, CRC, Disease, Mortality, Colonoscopy, Patient, Large intestine, Fear, ECLIPSE, Helmy Eltoukhy, Cancer, Samsung Medical Center, Medical imaging

SINGAPORE, Nov. 12, 2023 /PRNewswire/ -- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced that it has launched its blood-based colorectal cancer screening test, ShieldTM, in collaboration with Samsung Medical Center in South Korea.

Key Points: 
  • SINGAPORE, Nov. 12, 2023 /PRNewswire/ -- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced that it has launched its blood-based colorectal cancer screening test, ShieldTM, in collaboration with Samsung Medical Center in South Korea.
  • "The Shield blood test can broaden the range of choices for colorectal cancer screening.
  • "We are pleased to be able to help address the high rates of colorectal cancer in South Korea by introducing the Shield test at Samsung Medical Center," said Simranjit Singh, Chief Executive Officer of Guardant Health Asia, Middle East & Africa.
  • "We are confident that this revolutionary screening test will help healthcare professionals detect colorectal cancer early, when it's most treatable, with a simple blood draw."

Guardant Health launches Shield blood-based screening test for colorectal cancer in South Korea

Retrieved on: 
Lundi, novembre 13, 2023
Shield, DNA, Colorectal cancer, Neoplasm, CRC, Disease, Mortality, Colonoscopy, Patient, Large intestine, Fear, ECLIPSE, Helmy Eltoukhy, Cancer, Samsung Medical Center, Medical imaging

SINGAPORE, Nov. 13, 2023 /PRNewswire/ -- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced that it has launched its blood-based colorectal cancer screening test, ShieldTM, in collaboration with Samsung Medical Center in South Korea.

Key Points: 
  • SINGAPORE, Nov. 13, 2023 /PRNewswire/ -- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced that it has launched its blood-based colorectal cancer screening test, ShieldTM, in collaboration with Samsung Medical Center in South Korea.
  • "The Shield blood test can broaden the range of choices for colorectal cancer screening.
  • "We are pleased to be able to help address the high rates of colorectal cancer in South Korea by introducing the Shield test at Samsung Medical Center," said Simranjit Singh, Chief Executive Officer of Guardant Health Asia, Middle East & Africa.
  • "We are confident that this revolutionary screening test will help healthcare professionals detect colorectal cancer early, when it's most treatable, with a simple blood draw."

AI-Powered Tumor Microenvironment Analysis Predicts Treatment Outcomes in NSCLC Patients with EGFR Mutation: Groundbreaking Studies to be Presented by Lunit at SITC 2023

Retrieved on: 
Mercredi, novembre 1, 2023
TKI, TILS, Patient, Neoplasm, The Cancer Genome Atlas, TCGA, NSCLC, PTEN, Progression-free survival, Biomarker, Therapy, Booth, ICI, BRCA1, Data, PFS, PIK3CA, Phenotype, Inflammation, TIL, Samsung Medical Center, BRCA2, OR, TNBC, IL1A, SITC, Immunotherapy, Methylation, ITIL, Annual general meeting, Breast cancer, Triple-negative breast cancer, Gene, Tumor microenvironment, Lung cancer, Society, IL17A, Cancer, TFI, TME, STIL, Mutation, EGFR, Medical imaging

The study found that EGFR-TKI affects the immune landscape of EGFR-mutated NSCLC as higher PD-L1 expression and differential immune phenotypes.

Key Points: 
  • The study found that EGFR-TKI affects the immune landscape of EGFR-mutated NSCLC as higher PD-L1 expression and differential immune phenotypes.
  • Patients with an inflamed immune phenotype after EGFR-TKI treatment showed a more favorable response to subsequent immune checkpoint inhibitors (ICI) treatment.
  • Another study investigated the effect of tumor fragmentation index (TFI), the number of tumor fragments per total tumor area, in TME.
  • Visit Lunit's booth at SITC 2023 at Booth #227 to learn more about these pioneering studies.

First Immunotherapy Success in TKI-Resistant Lung Cancer Setting Demonstrates Power of AI-driven Immune Phenotyping by Lunit SCOPE IO - newly published in JCO

Retrieved on: 
Mardi, octobre 24, 2023
TKI, Bevacizumab, Patient, Pemetrexed, Arm, PC, NSCLC, Carboplatin, CDX, ESMO, Progression-free survival, III, Therapy, Lung cancer, Cisplatin, PFS, European Society for Medical Oncology, Phenotype, Research, TIL, JCO, Journal, Samsung Medical Center, ALK, Journal of Clinical Oncology, Annual general meeting, Immunotherapy, H&E, ORR, Oncology, ABCP, Mutation, EGFR, Pharmaceutical industry, Medical imaging

Against the backdrop of growing interest and need for an AI biomarker in medical practices, this marks the second time a study utilizing Lunit SCOPE IO has been published in the prestigious JCO.

Key Points: 
  • Against the backdrop of growing interest and need for an AI biomarker in medical practices, this marks the second time a study utilizing Lunit SCOPE IO has been published in the prestigious JCO.
  • Lunit SCOPE IO, an AI-powered TIL analyzer for assessing immune phenotype from H&E, played a pivotal role in this research.
  • Immune phenotype as assessed by Lunit SCOPE IO showed predictive power in stratifying patients more likely to respond to ABCP treatment.
  • "We aim for Lunit SCOPE IO to continue to make immune phenotyping a quantitative biomarker readily accessible for research, clinical use, and companion diagnostics (CDx) business."

ImmuneOncia Announces Phase 1 Results of CD47 Antibody at ESMO 2023

Retrieved on: 
Lundi, octobre 23, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Principal, PD-L1, Phase II, ESMO, Thrombocytopenia, Hemolytic anemia, Macrophage, European Society for Medical Oncology, CD47, Samsung Medical Center, SD, Liver cancer, Clinical trial, DLT, Breast cancer, Safety, Patient, Neutropenia, Medical imaging, Pharmaceutical industry, Vaccine

ImmuneOncia (CEO Heung Tae Kim) announced the results of its Phase 1a solid tumour clinical trial (IMC-002-K102 Study) of IMC-002, a CD47 monoclonal antibody, at the European Society for Medical Oncology (ESMO 2023) held in Madrid, Spain on October 23rd, 2023.

Key Points: 
  • ImmuneOncia (CEO Heung Tae Kim) announced the results of its Phase 1a solid tumour clinical trial (IMC-002-K102 Study) of IMC-002, a CD47 monoclonal antibody, at the European Society for Medical Oncology (ESMO 2023) held in Madrid, Spain on October 23rd, 2023.
  • The dose-escalation study aimed to assess the safety and tolerability, and to establish the recommended Phase 2 dose (RP2D) of IMC-002.
  • 92% of treatment-related adverse events (TRAE) were of Grade 1-2, with 94% occurring during the first treatment cycle.
  • In addition to the CD47 antibody IMC-002, ImmuneOncia also has a wide range of pipeline that includes the Phase 2 clinical-stage PD-L1 antibody IMC-001, and the preclinical-stage bispecific antibody IMC-201.

Treatment with RYBREVANT® (amivantamab-vmjw) and Lazertinib Plus Chemotherapy Showed Durable Progression-Free Survival in Patients with Previously Treated EGFR-Mutated Advanced Non-Small Cell Lung Cancer

Retrieved on: 
Lundi, septembre 11, 2023
WCLC, Neutropenia, Bispecific monoclonal antibody, Janssen Pharmaceuticals, Neoplasm, Samsung Medical Center, Drug, Lung cancer, International Association, TKI, Medicine, NSCLC, Carboplatin, PFS, Trial of the century, Rash, Amivantamab, HIV disease progression rates, Patient, EGFR, MET, Johnson & Johnson, Sungkyunkwan University, Abstract, Pemetrexed, Safety, Disease, Pharmaceutical industry

SINGAPORE, Sept. 11, 2023 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced follow-up results from the Phase 1b/2 CHRYSALIS-2 study cohort evaluating the safety and tolerability of the combination of RYBREVANT® (amivantamab-vmjw), a bispecific antibody targeting epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition (MET), with lazertinib, an oral third-generation EGFR tyrosine kinase inhibitor (TKI), plus platinum-based chemotherapy (carboplatin and pemetrexed) in patients with relapsed/refractory non-small cell lung cancer (NSCLC) and EGFR mutations. These findings are being presented at the International Association for the Study of Lung Cancer (IASLC) 2023 World Congress on Lung Cancer (WCLC) from September 9-12 in Singapore.1

Key Points: 
  • Resistance in patients is typically diverse and polyclonal, meaning their tumors can have more than one type of resistance caused by different pathways.
  • Results from the RYBREVANT®, lazertinib and chemotherapy combination cohort (n=20), were featured in a mini oral presentation ( Abstract #MA13.06 ) at the IASLC 2023 WCLC.
  • Five patients were treated beyond progression, with a median incremental treatment duration of 4.2 months.
  • "These results provide important insights into the treatment of patients with advanced non-small cell lung cancer with EGFR-mutated disease who have progressed on the current standard of care.